Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Apellis Pharmaceuticals Inc (APLS)  
$23.80 0.69 (2.99%) as of 4:30 Fri 10/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 132,769,000
Market Cap: 3.16(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $16.36 - $35.42
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 532,414 537,414 640,851 1,563,327
Total Sell Value $13,072,125 $13,165,975 $16,250,934 $68,980,794
Total People Sold 5 5 12 14
Total Sell Transactions 17 18 63 135
End Date 2025-07-06 2025-04-04 2024-10-04 2023-10-05

   
Records found: 819
  Page 1 of 33  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Dunlop A. Sinclair   –       •      –    2025-09-30 4 AS $0.00 $0 I/I (3,837) 30,142 5%     
   Dunlop A. Sinclair   –       •      –    2025-09-30 4 AS $22.58 $702,057 I/I (31,092) 33,979 5%     
   Dunlop A. Sinclair   –       •      –    2025-09-19 4 AS $0.00 $0 I/I (3,837) 65,071 3%     
   Dunlop A. Sinclair   –       •      –    2025-09-19 4 AS $22.95 $713,561 I/I (31,092) 68,908 3%     
   Watson David O. General Counsel   •       •      –    2025-09-16 4 AS $24.34 $121,700 D/D (5,000) 118,730 -0%     
   Chopas James George VP/Chief Accounting Officer   •       •      –    2025-09-15 4 S $24.19 $4,572 D/D (189) 53,468 5%     
   Watson David O. General Counsel   •       –      –    2025-09-10 4 S $26.17 $523,400 I/I (20,000) 50,136 11%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2025-09-08 4 AS $27.83 $278,300 I/I (10,000) 60,396 -12%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2025-09-08 4 AS $27.86 $911,830 D/D (32,729) 110,936 -12%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2025-09-08 4 OE $10.03 $150,450 D/D 15,000 143,665     -
   Chopas James George VP/Chief Accounting Officer   •       •      –    2025-09-02 4 S $28.08 $15,386 D/D (548) 53,657 18%     
   Boucher Kelley Chief People Officer   •       •      –    2025-09-02 4 A $0.00 $0 D/D 30,476 97,658     -
   Francois Cedric Chief Executive Officer   •       •      –    2025-08-28 4 S $28.39 $1,418,450 I/I (49,963) 307,946 18%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-08-27 4 S $28.19 $4,934,293 I/I (175,037) 357,909 18%     
   Meltzer Leslie Chief Research and Development   •       •      –    2025-08-26 4 A $0.00 $0 D/D 61,804 61,804     -
   Watson David O. General Counsel   •       •      –    2025-08-18 4 AS $27.80 $139,000 D/D (5,000) 123,730 -13%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-17 4 AS $20.21 $398,735 D/D (19,725) 331,605 19%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-17 4 OE $4.31 $38,777 D/D 8,997 351,330     -
   Watson David O. General Counsel   •       •      –    2025-07-16 4 AS $19.55 $97,750 D/D (5,000) 128,730 21%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-15 4 AS $20.09 $38,168 D/D (1,900) 342,333 23%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-15 4 OE $4.31 $3,448 D/D 800 344,233     -
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-14 4 AS $20.19 $2,774,923 D/D (137,465) 343,433 20%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-14 4 OE $4.31 $281,025 D/D 65,203 480,898     -
   Chopas James George VP/Chief Accounting Officer   •       •      –    2025-06-18 4 A $0.00 $0 D/D 6,250 54,205     -
   Watson David O. General Counsel   •       •      –    2025-06-16 4 AS $18.77 $93,850 D/D (5,000) 133,730 30%     

  819 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 33
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed